Potential Phenotype-Genotype Correlation in Marfan Syndrome: When Less is More?

Circulation: Cardiovascular Genetics

Volumn 8, Issue 2, 2015, Pages 256-260

  Dietz, Harry C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adrenergic beta 1 receptor blockers; aneurysm; angiotensin receptor blockers; Editorials; Marfan syndrome; phenotype genotype correlation; transforming growth factor beta

Indexed keywords

ATENOLOL; FIBRILLIN 1; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; PROPRANOLOL; TRANSFORMING GROWTH FACTOR BETA; ACTIN BINDING PROTEIN;

AORTA ROOT; EXTRACELLULAR MATRIX; FRAMESHIFT MUTATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INDEL MUTATION; MARFAN SYNDROME; MOLECULAR PATHOLOGY; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DOMINANT GENE; FEMALE; HAPLOINSUFFICIENCY; MALE;

FEMALE; GENES, DOMINANT; HAPLOINSUFFICIENCY; HUMANS; LOSARTAN; MALE; MARFAN SYNDROME; MICROFILAMENT PROTEINS;

EID: 84942881993     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.115.001040     Document Type: Review

References (41)

1. Franken R, den Hartog A, Radonic T, Micha D, Maugeri A, van Dijk FS, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan Syndrome. Circ Cardiovasc Genet. 2015;8:383-388. doi: 10.1161/CIRCGENETICS.114.000950.
2. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest. 2004;114:172-181. doi: 10.1172/JCI20641.
3. Schrijver I, Liu W, Odom R, Brenn T, Oefner P, Furthmayr H, et al. Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am J Hum Genet. 2002;71:223-237. doi: 10.1086/341581.
4. McGettrick AJ, Knott V, Willis A, Handford PA. Molecular effects of calcium binding mutations in Marfan syndrome depend on domain context. Hum Mol Genet. 2000;9:1987-1994.
5. Vollbrandt T, Tiedemann K, El-Hallous E, Lin G, Brinckmann J, John H, et al. Consequences of cysteine mutations in calcium-binding epidermal growth factor modules of fibrillin-1. J Biol Chem. 2004;279:32924-32931. doi: 10.1074/jbc.M405239200.
6. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem. 2003;278:2750-2757. doi: 10.1074/jbc.M209256200.
7. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33:407-411. doi: 10.1038/ng1116.
8. Lindsay ME, Dietz HC. The genetic basis of aortic aneurysm. Cold Spring Harb Perspect Med. 2014;4:a015909. doi: 10.1101/cshperspect.a015909.
9. Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al.; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012;44:916-921. doi: 10.1038/ng.2348.
10. Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet. 2012;44:922-927. doi: 10.1038/ng.2349.
11. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37:275-281. doi: 10.1038/ng1511.
12. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355:788-798. doi: 10.1056/NEJMoa055695.
13. van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011;43:121-126. doi: 10.1038/ng.744.
14. Carmignac V, Thevenon J, Adès L, Callewaert B, Julia S, Thauvin-Robinet C, et al. In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome. Am J Hum Genet. 2012;91:950-957. doi: 10.1016/j. ajhg.2012.10.002.
15. Doyle AJ, Doyle JJ, Bessling SL, Maragh S, Lindsay ME, Schepers D, et al. Mutations in the TGF- repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat Genet. 2012;44:1249-1254. doi: 10.1038/ng.2421.
16. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432. doi: 10.1172/JCI38136.
17. Li W, Li Q, Jiao Y, Qin L, Ali R, Zhou J, et al. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J Clin Invest. 2014;124:755-767. doi: 10.1172/JCI69942.
18. Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, et al. Dimorphic effects of transforming growth factor-beta signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan Syndrome. Arterioscler Thromb Vasc Biol. Januray 22, 2015. doi: 10.1161/ATVBAHA.114.305150. http://atvb.ahajournals. org/lookup/doi/10.1161/ATVBAHA.114.305150. Accessed January 22, 2015.
19. Arteaga-Solis E, Gayraud B, Lee SY, Shum L, Sakai L, Ramirez F. Regulation of limb patterning by extracellular microfibrils. J Cell Biol. 2001;154:275-281.
20. Détaint D, Faivre L, Collod-Beroud G, Child AH, Loeys BL, Binquet C, et al. Cardiovascular manifestations in men and women carrying a FBN1 mutation. Eur Heart J. 2010;31:2223-2229. doi: 10.1093/eurheartj/ehq258.
21. Faivre L, Collod-Beroud G, Callewaert B, Child A, Binquet C, Gautier E, et al. Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation. Eur J Hum Genet. 2009;17:491-501. doi: 10.1038/ejhg.2008.207.
22. Loeys B, De Backer J, Van Acker P, Wettinck K, Pals G, Nuytinck L, et al. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat. 2004;24:140-146. doi: 10.1002/humu.20070.
23. Hilhorst-Hofstee Y, Hamel BC, Verheij JB, Rijlaarsdam ME, Mancini GM, Cobben JM, et al. The clinical spectrum of complete FBN1 allele deletions. Eur J Hum Genet. 2011;19:247-252. doi: 10.1038/ejhg.2010.174.
24. Nijbroek G, Sood S, McIntosh I, Francomano CA, Bull E, Pereira L, et al. Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet. 1995;57:8-21.
25. Gao L, Mao Q, Wen D, Zhang L, Zhou X, Hui R. The effect of beta-blocker therapy on progressive aortic dilatation in children and adolescents with Marfan's syndrome: a meta-analysis. Acta Paediatr. 2011;100:e101-e105. doi: 10.1111/j.1651-2227.2011.02293.x.
26. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121. doi: 10.1126/science.1124287.
27. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Larivière R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens. 2005;23:1895-1903.
28. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789-791.
29. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008;358:2787-2795. doi: 10.1056/NEJMoa0706585.
30. Chiu HH, Wu MH, Wang JK, Lu CW, Chiu SN, Chen CA, et al. Losartan added to ?-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc. 2013;88:271-276. doi: 10.1016/j.mayocp.2012.11.005.
31. Pees C, Laccone F, Hagl M, Debrauwer V, Moser E, Michel-Behnke I. Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol. 2013;112:1477-1483. doi: 10.1016/j.amjcard.2013.06.019.
32. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34:3491-3500. doi: 10.1093/eurheartj/eht334.
33. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al; Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371:2061-2071. doi: 10.1056/NEJMoa1404731.
34. Ladouceur M, Fermanian C, Lupoglazoff JM, Edouard T, Dulac Y, Acar P, et al. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol. 2007;99:406-409. doi: 10.1016/j.amjcard.2006.08.048.
35. Rossi-Foulkes R, Roman MJ, Rosen SE, Kramer-Fox R, Ehlers KH, O'Loughlin JE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol. 1999;83:1364-1368.
36. Salim MA, Alpert BS, Ward JC, Pyeritz RE. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol. 1994;74:629-633.
37. Tahernia AC. Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and beta-blockers. South Med J. 1993;86:305-310.
38. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011;332:361-365. doi: 10.1126/science.1192152.
39. Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, et al. Noncanonical TGF signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011;332:358-361. doi: 10.1126/science.1192149.
40. Li L, Cai H, Liu H, Guo T. Beta-adrenergic stimulation activates protein kinase Cepsilon and induces extracellular signal-regulated kinase phosphorylation and cardiomyocyte hypertrophy. [published online ahead of print]. Mol Med Rep. 2015;doi:10.3892/mmr.2015.3316.
41. Galle J. Reduction of proteinuria with angiotensin receptor blockers. Nat Clin Pract Cardiovasc Med. 2008;5(suppl 1):S36-S43. doi: 10.1038/ncpcardio0806.